Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension

Liver Transplantation

Volumn 13, Issue 11, 2007, Pages 1506-1514

  Ricci, Giovanni L ^a   Melgosa, Maria Teresa ^b   Burgos, Felip ^b   Valera, José Luis ^b   Pizarro, Sandra ^b   Roca, Josep ^b   Rodriguez Roisin, Roberto ^b   Barberà, Joan Albert ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ISOSORBIDE 5 NITRATE; NITRIC OXIDE; PROSTACYCLIN;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; HEART INDEX; HUMAN; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG GAS EXCHANGE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PATIENT SELECTION; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REFERENCE VALUE; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; EPOPROSTENOL; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; ISOSORBIDE DINITRATE; LUNG; MALE; MIDDLE AGED; NITRIC OXIDE; PULMONARY CIRCULATION; RESPIRATORY FUNCTION TESTS; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 36448952726     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21173     Document Type: Article

References (43)

1. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duraux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-1166.
2. Taura P, Garcia-Valdecasas JC, Beltran J, Izquierdo E, Navasa M, Sala-Blanch J, et al. Moderate pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg 1996;83:675-680.
3. Rodriguez-Roisin R, Krowka MJ, Herve Ph, Fallon MB, ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Eur Respir J 2004;24:681-680.
4. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines for the diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension and the European Society of Cardiology. Eur Heart J 2004;25:2243-2278.
5. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium channel blockers in primary pulmonary hypertension Eur Resp J 1998;12:265-270.
6. Sitbon O, Humbert M, Jais X, Ioos V, Hamid Am, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111.
7. Morales-Blanhir J, Santos S, de Jover L, Sala E, Paré C, Roca J, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004;98: 225-234.
8. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institute of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989;140:1623-1630.
9. Ramsay MA, Schmidt A, Hein HA, Nguyen AT, Lynch K, East CA, et al. Nitric oxide does not reverse pulmonary hypertension associated with end-stage liver disease: a preliminary report. Hepatology 1997;25:524-527.
10. Findlay JY, Harrison BA, Plevak DJ, Krowka MJ. Inhaled nitric oxide reduces pulmonary artery pressure in portopulmonary hypertension. Liver Transpl 1999;5:381-387.
11. Ramsay MA, Spikes C, East CA, Lynch K, Hein HA, Ramsay KJ, Klintmalm GB. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology 1999;90:299-301.
12. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648.
13. Acosta F, Sansano T, Palenciano CG, Domemenech P, Falcon L, Robles R, et al. Portopulmonary hypertension and liver transplantation: hemodynamic consequences at reperfusion. Transplant Proc 2005;37:3865-3866.
14. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevsky HI. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005;11:1107-1111.
15. Ota K, Shijo H, Kokawa H, Kubara K, Kim T, Akiyoshi N, et al. Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. J Gastroenterol Hepatol 1995;10:198-204.
16. Garcia-Pagan JC, Feu F, Luca A, Fernández M, Pizcueta P, Bosch J, Rodés J. Nicardipine increases hepatic blood flow and the hepatic clearance of indocyanine green in patients with cirrhosis. J Hepatol 1994;20:792-796.
17. Iwao T, Toyonaga A, Ikegami M, Sugawara H, Sumino M, Takagi K, et al. Nicardipine infusion improved hepatic function but failed to reduce hepatic venous pressure gradient in patients with cirrhosis. Am J Gastroenterol 1992; 87:326-331.
18. Wang YW, Lin HC, Yang YY, Hou MC, Lee SD. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. J Gastroenterol 2006; 41:593-597.
19. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006;28:563-567.
20. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-508.
21. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005;258: 199-215.
22. Segal ES, Vallette C, Oster L, Bouley L, Edfjall C, Herrmann P, et al. Risk management strategies in the post marketing period: safety experience with the US and European Bosentan surveillance programes. Drug Saf 2005; 28:971-980.
23. Ribas J, Angrill J, Barberà JA, Garcia-Pagán JC, Roca J, Bosch J, et al. Isosorbide nononitrate in the treatment of portopulmonary hypertension associated with portal hypertension. Eur Respir J 1999;13:120-112.
24. Navasa M, Chesta J, Bosch J, Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989;96:1110-1118.
25. Garcia-Pagan JC, Feu F, Navasa M, Bru C, Ruiz del Arbol L, Bosch J, Rhodes J. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990;11:189-195.
26. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996;347:436-440.
27. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension [Review]. J Am Coll Cardiol 2004;43(Suppl S):40S-47S.
28. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(Suppl):35S-62S.
29. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST, Rubin LJ. Distinctive clinical features of porto-pulmonary hypertension. Chest 1997;112:980-986.
30. Humbert M, Sitbon O, Chaouat A, Bertocchi J, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France. Results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.
31. Kapoor D, Jalan R. Vascular hyporesponsiveness in cirrhosis - many facets of a common problem. Eur J Clin Invest 2001;31:95-97.
32. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group. J Am Coll Cardiol 2000;35:176-182.
33. Jolliet P, Bulpa P, Thorens JB, Ritz M, Chevrolet JC. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. Thorax 1997;52:369-372.
34. Shijo H, Yokoyama M, Ota K, Kokawa H, Kubara K, Kim T, et al. Nitrate kinetics in patients with compensated cirrhosis: correlation with hemodynamica. Am J Gastroenterol 1996;91:2190-2194.
35. Lai OF, Chow PK, Tan S, Song IC, Soo KC, Aw SE, et al. Changes in prostaglandins and nitric oxide levels in the hyperdynamic circulation following hepatic resection. J Gastroenterol Hepatol 2000;15:895-901.
36. Mandell MS, Duke J. Nitric oxide reduces pulmonary hypertension during hepatic transplantation. Anesthesiology 1994;81:1538-1542.
37. Bruix J, Bosch J, Kravetz D, Mastai R, Rodes J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985;88:430-435.
38. Zardi EM, Picardi A, Ambrosino G, Serio A, Costantino S, Dobrina A. Hemodynamic effects of a prostacyclin analog (ILOPROST) on portal flow velocity and volume and visceral artery circulation in patients with lower limb arteriopathy. Ultrasound Med Biol 2003;29:209-213.
39. Guarner C, Soriano G, Such J, Teixido M, Ramis I, Bulbena O, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992;102:303-309.
40. 2 in the formation and maintenance of hyperdynamic circulatory state of portal hypertensive rats. World J Gastroenterol 2005;11:752-755.
41. TadrosT, Taber DL, Herndon DH. Opposite effect of prostacyclin on hepatic blood flow and oxygen consumption after burn and sepsis. Ann Surg 2004;239:67-74.
42. Battaglia SE, Pretto JJ, Irving LB, Jones RM, Angus PW. Resolution of gas exchange abnormalities and intrapulmonary shunting following liver transplantation. Hepatology 1997;25:1228-1232.
43. Martínez-Pallí G, Gómez FP, Barberà JA, Navasa M, Roca J, Rodriguez-Roisin R, et al. Persistent diffusion impairment after liver transplant in hepatopulmonary syndrome. World J Gastroenterol 2006;12:5878-5883.